Contradictory KRAS mutation test results in a patient with metastatic colon cancer: A clinical dilemma in the era of personalized medicine

Keyphrases

• 5-fluorouracil (5-FU) 33%
• Anti-EGFR 33%
• Antibody-dependent Cellular Cytotoxicity 33%
• Cetuximab 100%
• Clinical Dilemma 100%
• Colorectal Cancer 33%
• Combination Chemotherapy 33%
• Decision-making Process 33%
• Disease Progression 33%
• First-line Therapy 33%
• FOLFIRI 33%
• Heterogeneous Tumors 33%
• Irinotecan 33%
• KRAS mutation 100%
• KRAS Oncogene 66%
• Leucovorin 33%
• Metastatic Colorectal Cancer (mCRC) 100%
• Mutation Testing 100%
• Mutation-negative 33%
• Pathological Specimen 33%
• Personalized Medicine 100%
• Personalized Therapy 33%
• Reference Laboratory 33%
• Therapeutic Benefits 33%
• Tumor 33%
• Wild-type KRAS 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Cetuximab 75%
• Chemotherapy 25%
• Colorectal Carcinoma 25%
• Cytotoxicity 25%
• Disease Exacerbation 25%
• Epidermal Growth Factor Receptor 100%
• Fluorouracil 25%
• Folinic Acid 25%
• Irinotecan 25%
• Metastatic Colon Cancer 100%
• Metastatic Colorectal Cancer 25%
• Neoplasm 50%
• Panitumumab 25%
• Receptor 25%

Medicine and Dentistry

• Antibody Dependent Cellular Cytotoxicity 25%
• FOLFIRI 25%
• Metastatic Colon Cancer 100%
• Panitumumab 25%